Rodorubicin is a synthetic anthracycline antibiotic that exhibits potent anticancer activity. It is a derivative of daunorubicin, with a key modification at the 13-position of the anthracycline ring system. This structural change enhances its ability to bind to DNA and inhibit DNA synthesis, leading to apoptosis (programmed cell death) in cancer cells. Notably, rodorubicin displays greater potency compared to daunorubicin, particularly against certain leukemia subtypes. Its clinical utility extends to the treatment of various cancers, including acute myeloid leukemia, breast cancer, and ovarian cancer. Ongoing research explores rodorubicin's potential in combination therapy, targeting specific cancer cell subtypes, and addressing its associated toxicity concerns.'
rodorubicin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57097 |
| CHEMBL ID | 3989540 |
| SCHEMBL ID | 8693 |
| MeSH ID | M0159253 |
| Synonym |
|---|
| rodorubicin [inn] |
| rodorubicin |
| rodorubicine |
| 96497-67-5 |
| rodorubicina [spanish] |
| rodorubicinum |
| rodorubicina |
| (1s,3r,4r)-3-ethyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-1-naphthacenyl o-3,6-dideoxy-alpha-l-erythro-hexopyranos-4-ulosyl-(1->4)-o-2,6-dideoxy-alpha-l-lyxo-hexopyrano |
| rodorubicinum [latin] |
| xcz4d2241y , |
| (1s,3r,4r)-3-ethyl-1,2,3,4,6,11-hexahydro-3,5,10,12-tetrahydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-1-naphthacenyl o-3,6-dideoxy-alpha-l-erythro-hexopyranos-4-ulosyl-(1-4)-o-2,6-dideoxy-alpha-l-lyxo-hexopyranos |
| rodorubicine [french] |
| unii-xcz4d2241y |
| SCHEMBL8693 |
| (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-(dimethylamino)-5-[[(1r,3r,5s,8s,10s,12s,14s)-5,14-dimethyl-6-oxo-2,4,9,13-tetraoxatricyclo[8.4.0.03,8]tetradecan-12-yl]oxy]-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4 |
| CHEMBL3989540 |
| Q27293780 |
| AKOS040747414 |
Rodorubicin is a new tetraglycosidic anthracycline. It was detected because of its activity against human tumors in a human tumor based screening system.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rodorubicin is a new tetraglycosidic anthracycline, which was detected because of its activity against human tumors in a human tumor based screening system. " | ( Rodorubicin, a new tetraglycosidic anthracycline. Kraemer, HP; Sedlacek, HH, 1988) | 3.16 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||